Want to see SE:ONCO full AI Analyst Report?
Oncopeptides AB (ONCO) Income Statement
Oncopeptides AB Income Statement
Last quarter (Q2 2026), Oncopeptides AB's total revenue was $31.10M, an increase of 62.12% from the same quarter last year. In Q2, Oncopeptides AB's net income was $-54.71M. See Oncopeptides AB’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 71.12M | $ 31.65M | $ 35.22M | $ 8.36M | $ 118.30M | |
| $ 59.00M | $ 28.98M | $ 36.30M | $ 8.35M | $ 65.17M | |
| $ 287.93M | $ 312.48M | $ 289.75M | $ 357.70M | $ 1.49B | |
| Depreciation and Amortization | $ 9.67M | $ 9.75M | $ 11.04M | $ 17.16M | $ 14.99M |
| $ -219.26M | $ -261.81M | $ -231.62M | $ -319.64M | $ -1.41B | |
| $ -225.89M | $ -283.50M | $ -253.45M | $ -349.35M | $ -1.42B | |
| $ -22.28M | $ -711.00K | $ 5.00M | $ 11.67M | $ -455.00K | |
| $ -248.17M | $ -284.21M | $ -248.45M | $ -337.68M | $ -1.42B | |
| $ -249.59M | $ -284.61M | $ -249.11M | $ -337.95M | $ -1.43B | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.10 | $ -1.71 | $ -1.96 | $ -4.11 | $ -19.00 |
| Diluted EPS | $ -1.10 | $ -1.71 | $ -1.96 | $ -4.11 | $ -19.00 |
| Weighted Average Shares Outstanding | 226.90M | 166.44M | 126.84M | 82.32M | 75.29M |
| Weighted Average Shares Outstanding (Diluted) | 226.90M | 166.44M | 126.84M | 82.32M | 75.29M |
Currency in SEK